A major meeting is due to be held in Paris on 14th-16th February, bringing together world experts on CAR-T cell therapy.
The first European CAR-T Cell Meeting will be hosted by the European Haematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT).
The meeting aims to raise awareness among patients, physicians, nurses, hospitals and the whole health care system of the practicalities of providing CAR-T cell therapy.
Announcing the meeting, Prof Christian Chabannon of the EBMT said the two organisations “unite in designing this first-ever European Meeting which represents an amazing educational opportunity for health care professionals to get practical information to safely administer CAR-T Cells to a growing number of patients, both in Europe and worldwide."
Prof Hermann Einsele of the EHA added: "Experts with various backgrounds and expertise will share their knowledge about CAR-T Cell Therapy and provide an overview of their current and future applications in cancer treatment, and how this translates in health care organisations.”
CAR-T cell therapy is a new type of treatment where T cells from a patient are genetically modified then reinfused so that they look for and kill cancer cells.
The cells are modified in the lab to produce chimeric antigen receptors on their surface. These receptors recognise specific proteins on the cancer cells, and signal to the T cells and other immune cells to destroy them.
Disclaimer: The news stories shared on this site are used as a way to inform our members and followers of updates and relevant information happening in Haematology. The BSH does not endorse the content of news items from external sources, and is not in a position to verify the findings, accuracy or the source of any studies mentioned. Any medical or drugs information is provided as an information resource only, and is not to be relied on for any diagnostic or treatment purposes.
News service provided by Englemed News http://www.englemed.co.uk/